Prostate Cancer Clinical Trials in Cleveland

Showing 341-360 of 374 trials

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005848

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have progressive, metastatic prostate cancer that has not responded to hormone therapy.

Prostate Cancer

Fox Chase Cancer Center7 participantsStarted Apr 2000

Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

NCT00002723

Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.

Prostate Cancer

National Cancer Institute (NCI)390 participantsStarted Jan 1996

Chicago, Illinois, United States • Chicago, Illinois, United States • Urbana, Illinois, United States +24 more locations

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Prostate Cancer Trials in Other Cities

Reiki/Energy Healing in Prostate Cancer

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

Other Conditions in Cleveland